Hiroaki Nomori1, Ikuo Yamazaki2, Atsushi Shiraishi3, Tetsuya Adachi2, Masaya Kanno4. 1. Department of General Thoracic Surgery, Kashiwa Kousei General Hospital, 617 Shikoda, Kashiwa City, 277-8551, Chiba, Japan. Electronic address: hnomori@qk9.so-net.ne.jp. 2. Department of Radiology, Kameda Medical Center, Chiba, Japan. 3. Department of Emergency and Trauma Center, Kameda Medical Center, Chiba, Japan. 4. Department of Medical Engineering, Kameda Medical Center, Chiba, Japan.
Abstract
OBJECTIVES: To evaluate local control and complications of cryoablation for T1N0M0 non-small cell lung cancer using liquid nitrogen. METHODS: This is a retrospective observational study on 101 patients with T1N0M0 NSCLC who underwent cryoablation between 2013 and 2019. Exclusion criteria included tumors without pathological diagnosis. The study population was divided into 4 groups according to the quartile of maximum tumor diameter. The study outcomes included local control, recurrence-free survival (RFS), treatment complications, and change in pulmonary function. Median follow-up period was 35 months. RESULTS: Tumor diameter was divided into ≤0.9 cm (n = 21), 1.0-1.2 (n = 29), 1.3-1.7 (n = 24), and ≥1.8 (n = 27). Ten patients experienced local recurrences, which were observed none in both the groups of ≤0.9 cm and 1.0-1.2 cm (0%), one in the group of 1.3-1.7 cm (4%), and the other 9 in the group of ≥1.8 cm (33 %), indicating the local control to be better in smaller tumors (p < 0.001). The 3-year RFS was 86 % in ≤0.9 cm, 97 % in 1.0-1.2 cm, 92 % in 1.3-1.7 cm, and 53 % in≥1.8 cm, indicating the survival to be better in smaller tumors (p < 0.001). No patient had treatment-related mortality. The most frequent complication was pneumothorax, with a rate of 24 %. Forced expiratory volume in 1 s at 6 months after cryoablation was 97 ± 10 % of the pretreatment one. CONCLUSION: The local control and recurrence-free survival of cryoablation for T1N0M0 NSCLC was satisfactory for tumors <1.8 cm. While main complication was pneumothorax, the decrease of pulmonary function was just 3%.
OBJECTIVES: To evaluate local control and complications of cryoablation for T1N0M0 non-small cell lung cancer using liquid nitrogen. METHODS: This is a retrospective observational study on 101 patients with T1N0M0 NSCLC who underwent cryoablation between 2013 and 2019. Exclusion criteria included tumors without pathological diagnosis. The study population was divided into 4 groups according to the quartile of maximum tumor diameter. The study outcomes included local control, recurrence-free survival (RFS), treatment complications, and change in pulmonary function. Median follow-up period was 35 months. RESULTS:Tumor diameter was divided into ≤0.9 cm (n = 21), 1.0-1.2 (n = 29), 1.3-1.7 (n = 24), and ≥1.8 (n = 27). Ten patients experienced local recurrences, which were observed none in both the groups of ≤0.9 cm and 1.0-1.2 cm (0%), one in the group of 1.3-1.7 cm (4%), and the other 9 in the group of ≥1.8 cm (33 %), indicating the local control to be better in smaller tumors (p < 0.001). The 3-year RFS was 86 % in ≤0.9 cm, 97 % in 1.0-1.2 cm, 92 % in 1.3-1.7 cm, and 53 % in≥1.8 cm, indicating the survival to be better in smaller tumors (p < 0.001). No patient had treatment-related mortality. The most frequent complication was pneumothorax, with a rate of 24 %. Forced expiratory volume in 1 s at 6 months after cryoablation was 97 ± 10 % of the pretreatment one. CONCLUSION: The local control and recurrence-free survival of cryoablation for T1N0M0 NSCLC was satisfactory for tumors <1.8 cm. While main complication was pneumothorax, the decrease of pulmonary function was just 3%.